INTERVIEW: Cook MyoSite Eyes Japan As Cell Therapy Trials Progress
This article was originally published in PharmAsia News
Executive Summary
In the wake of supportive regulations introduced in 2014, more and more firms in the regenerative medicines space are eyeing Japan as an attractive market. US-based Cook MyoSite is no exception.
You may also be interested in...
US FDA May Reconsider RMAT Requests If Resubmitted With Sufficient Clinical Data
Rejection of an RMAT request does not mean necessarily mean the FDA won't grant one. The agency will accept new clinical data to support the application through a “reconsideration” process, industry official says.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.